Guibert et al. showed that the presence of a phosphatase and tensin homolog (PTEN) or a serine/threonine kinase 11 (STK11) mutation was correlated with early progression in NSCLC patients receiving anti PD-1 immunotherapy. The gene discussed is STK11; the disease is non-small cell lung carcinoma.